<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100955</url>
  </required_header>
  <id_info>
    <org_study_id>QU20170327</org_study_id>
    <nct_id>NCT03100955</nct_id>
  </id_info>
  <brief_title>A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer</brief_title>
  <official_title>A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qingdao University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the progression free survival in patients with extensive stage small cell lung&#xD;
      cancer treated with cisplatin and etoposide plus or not apatinib&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assess progression free survival, overall survival and toxicity of standard EP regimen&#xD;
      combined or not with VEGF tyrosine kinase inhibitor-apatinib. Response measured by RECIST&#xD;
      response criteria. Toxicity via physical exam, adverse event review, assessing signs and&#xD;
      symptoms, quality of life assessment and blood testing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>24 months</time_frame>
    <description>from the date of randomization to disease progression</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Progression Free Survival</condition>
  <arm_group>
    <arm_group_label>EP chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment or active comparator group contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EP chemotherapy plus apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib treatment or experimental group contains standard chemotherapy and apatinib, a VEGF tyrosine kinase inhibitor. It contains a platinum drug, a topoisomerase inhibitor and a VEGF-TKI. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI=apatinib, 500 mg, oral daily after chemotherapy, until disease progression or death or un-tolerated toxicites. Used drugs=cisplatinum and etoposide and apatinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin, etoposide</intervention_name>
    <description>The recommended regimen is cisplatin plus etoposide. cisplatin 75 mg/m2 iv on day 1, etoposide 120 mg/m2 iv on day 1-3, 3 weeks a cycle, total for 6 cycles is allowed.</description>
    <arm_group_label>EP chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin, etoposide, apatinib</intervention_name>
    <description>Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatin and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI apatinib oral daily after chemotherapy treatment. Apatinib 500mg oral, once a day, until disease progression or death or un-tolerated toxicites.</description>
    <arm_group_label>EP chemotherapy plus apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically verified SCLC, extensive stages&#xD;
&#xD;
          2. WHO performance status 0, 1, 2&#xD;
&#xD;
          3. Age 18 years or older&#xD;
&#xD;
          4. Treatment naive&#xD;
&#xD;
          5. Anticipated survival more than 3 months&#xD;
&#xD;
          6. HB &gt;90g/L, ANC&gt;1.5 x 109/L, Platelets &gt;80 x109 /L&#xD;
&#xD;
          7. No prognancy&#xD;
&#xD;
          8. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Limited stage disease&#xD;
&#xD;
          2. Metastastic meningitis, spinal compression, Tumor to main vesicular less than 5mm&#xD;
&#xD;
          3. Uncontrolled hypertension&#xD;
&#xD;
          4. Uncontrolled heart failure&#xD;
&#xD;
          5. Coagulation problem&#xD;
&#xD;
          6. Surgery, trauma, uncontrolled ulcer in 4 weeks.&#xD;
&#xD;
          7. Required by physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhuang Yu, MD, Ph. D</last_name>
    <role>Study Chair</role>
    <affiliation>Affiliated Hospital of Qingdao University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>keke nie, MD</last_name>
    <phone>(86)18561857907</phone>
    <email>niekekeqd@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>youxin ji, MD, Ph. D</last_name>
    <phone>(86)532-68665078</phone>
    <email>ji6677@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhuang Yu, MD</last_name>
      <phone>(86)18661805688</phone>
      <email>yuzhuang2002@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhuang Yu, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>March 26, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qingdao University</investigator_affiliation>
    <investigator_full_name>medley nie</investigator_full_name>
    <investigator_title>Secretary of clinical trials</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

